학술논문

Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial.
Document Type
Article
Source
Journal of Allergy & Clinical Immunology; 2024 Supplement, Vol. 153 Issue 2, pAB366-AB366, 1p
Subject
Language
ISSN
00916749